期刊文献+

OK-432肿瘤细胞疫苗对DBA/2小鼠舌癌生长抑制作用

OK-432 tumor cell vaccine inhibits tongue cancer growth in DBA/2 mice
下载PDF
导出
摘要 目的利用DBA/2小鼠移植舌癌荷瘤模型,探究OK-432肿瘤细胞疫苗对舌癌的抑制作用。方法以戊二醛为交联剂,使KLN-205细胞与OK-432产生交联,制备OK-432肿瘤细胞疫苗;将DBA/2小鼠随机分为4组,每组20只,分别右侧腹部皮下注射0.9%氯化钠注射液、OK-432、灭活的KLN-205细胞、OK-432疫苗,接种KLN-205肿瘤细胞后观察对比舌癌瘤体大小,并用统计学分析其结果。结果肿瘤大小除KLN-205组与对照组间差异没有统计学意义(P=0.094)外,其余各组间差异均有统计学意义,其中OK-432疫苗组肿瘤体积均小于其他3组。结论 OK-432肿瘤细胞疫苗能抑制小鼠舌癌的生长,具有一定的抗肿瘤效应。 Objective To investigate the inhibitory effects of OK-432 tumor cell vaccine on tongue cancer growth in DBA/2 mice by using the tongue cancer xenograft models. Methods The OK-432 tumor cell vaccine was prepared by inducing conjugation of OK-432 to squamous cell carcinoma (KLN-205) with 0.2% glutaraldehyde (GA). The DBA/2 mice were randomly allocated to receive subcutaneous injection of saline ( n=20), OK-432 (n=20), inacti-vated KLN-205 cells (n=20) and OK-432 tumor cell vaccine (n=20) on the right abdomen. This allowed assessment of the tumor size before and after KLN-205 cell inoculation. Results The tumor size was significantly different among the four groups except for OK-432 vaccine group compared with control group (P=0.094). Inoculation with OK-432 vaccine resulted in marked reduction in the tumor size compared with the remaining three groups. Conclusion OK-432 tumor cell vaccine can inhibit the growth of tongue cancer in mice, suggesting the potential anti-tumor effects.
出处 《中国药物与临床》 CAS 2014年第7期870-872,共3页 Chinese Remedies & Clinics
基金 国家自然科学基金(81141091)
关键词 癌症疫苗 DBA 2小鼠 KLN-205细胞 Cancer vaccines DBA/2 mice KLN-205 cell
  • 相关文献

参考文献7

  • 1Tabi Z,Man S. Challenges for cancer vaccine development [Jl. Adv Drug Deliv Rev,2006,58(8) :902-915.
  • 2Kim SY,Park HC,Yoon C,et al. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemother- apy in patients with curatively resected gastric carcinoma: a ran- domized phase Ⅲ trial[J]. Cancer, 1998,83 (10) : 2054-2059.
  • 3Sakamoto J,Teramukai S,Nakazato H,et al. Efficacy of adjuvant immunoehemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials [J]. J Immunother,2002,25(5):405- 412.
  • 4Ahmed SU,Okamoto M,Oshikawa T,et al. Antitumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like recep- tor 4[J ]. J Immunother. 2004.27(6) : 432-441.
  • 5Woolley SL,Smith DR,Quine S. Adult cystic hygroma: success- ful use of OK-432 (Picibanil)[J]. J Laryngul Otol,2008,122 (11) : 1260-1264.
  • 6Tano T,Okamoto M,Kan S,et al. Growth inhibition and apopto- sis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines[Jl. Oral Oncology,2012,48(8) :678-685.
  • 7Li X, Bukawa H, Hirota M,et al. Novel OK-432-conjugated tumor vaccines induce tumor-specific immunity against murine tongue cancer[J]. J Dent Res,2003,82(8):636-640.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部